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Only native products of Mycobacterium leprae, whether cell wall, cytosol, or membrane derived, can confer
protective immunity against challenge in the mouse footpad. Previously, recombinant proteins were shown to
be ineffective. The cell wall skeleton—the mycolyl-arabinogalactan-peptidoglycan complex—devoid of proteins
is not protective.
Largely as the result of the implementation of effective mul-
tiple-drug chemotherapy, the number of cases of leprosy
worldwide has plunged from approximately 10 million in 1985
to fewer than 700,000 in 1999 (27, 28). However, there are
large areas throughout the world in which heightened surveil-
lance and an apparent ineffectiveness of multiple-drug chemo-
therapy to fully sterilize all sources of infection have resulted in
a sizable increase of the estimated number of new cases (29,
30). As a result, the earlier, optimistic goal of reducing the
worldwide prevalence of the disease to less than one case per
10,000 population by the year 2000 was not achieved (29).
Thus, the prospects of a leprosy vaccine are being seriously
addressed for the first time since the early 1990s. The mouse
footpad model of leprosy, in use in only a few laboratories
today, is still the only laboratory means for testing vaccines.
The results of earlier efforts to produce a leprosy vaccine
have been mixed. An immunoprophylaxis trial in south India,
launched in 1991 with 171,400 volunteers, compared four vac-
cines: (i) a combination of Mycobacterium bovis BCG and
heat-killed Mycobacterium leprae (HKML); (ii) a cultivable
mycobacterium, called ICRC, originally isolated in Mumbai,
India, from a lepromatous nodule; (iii) another cultivable my-
cobacterium, isolated in New Delhi, India, and also from a
lepromatous nodule, called Mycobacterium w; and (iv) BCG.
Normal saline was employed as a placebo. BCG-HKML con-
ferred 64% protection and ICRC conferred 65.5% protection;
the other vaccines were ineffective (9). However, earlier trials
of HKML in Venezuela (5) and Malawi (10) showed no pro-
tection, perhaps because of poor quality control of the vaccines
or because the absence of a placebo obscured any protective
effects.
The first mouse study employing a subunit vaccine was that
of Shepard and Ribi (21), who demonstrated protection of
mice against M. leprae challenge in a hind footpad by admin-
istration of BCG cell walls emulsified in 7-n-hexyloctadecane.
Subsequently, Gelber et al. (7, 8) showed that immunization of
mice with crude cell wall fractions of M. leprae, as well as with
proteins derived from a pelleted fraction of sonicated M. lep-
rae, conferred significant protection against subsequent chal-
lenge with M. leprae in the footpad. Continuing with this ap-
proach, we have demonstrated that three fractions of M. leprae
all conferred protection against M. leprae infection when the
materials were administered emulsified in Freund’s incomplete
adjuvant (FIA) (14, 15). These three fractions were the follow-
ing: the soluble fraction of M. leprae from which much of the
soluble carbohydrates and lipids, especially lipoarabinoman-
nan (LAM), had been removed by extraction with Triton
X-114 [M. leprae soluble antigen minus LAM (MLSA-LAM)];
the remaining insoluble pellet of M. leprae (MLCwA); and the
insoluble pellet that had been extracted with Triton X-114
(MLCwA-LAM). However, pools of the recombinant versions
of some of the major protein antigens of M. leprae and M.
tuberculosis, emulsified in either FIA or monophosphoryl lipid
A, were all found to be ineffective in experiments in which
MLSA-LAM emulsified in monophosphoryl lipid A was again
shown to be protective (15). Reasoning that the failure of the
recombinant bacterial proteins to confer protection resulted
from the absence of suitable posttranslational changes, such as
glycosylation or esterification (6), a further study was under-
taken to examine the effects of more refined, well-defined
fractions of M. leprae on immunocompetent mice challenged in
the hind footpad with M. leprae.
Female BALB/c/ mice, purchased from CLEA JAPAN,
Inc., Meguro-ku, Japan, and housed at the National Institute
of Health, Nonthaburi, Thailand, under specific-pathogen-free
conditions, were divided among various groups, as shown in
Tables 1 and 2. HKML and fractions of M. leprae were pre-
pared at Colorado State University (13). The various materials,
suspended in phosphate-buffered saline (PBS) or emulsified in
FIA, were injected intradermally into each flank to groups of
12 to 15 mice in a dosage of 20 g per mouse on three occa-
sions 3 weeks apart. An additional group of 15 mice was ad-
ministered FIA. Twenty-eight days after the third injection, the
antigen-treated mice were inoculated with 5  103 M. leprae
each in the right hind footpad, and the adjuvant-treated and
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control mice were similarly inoculated in both hind footpads.
Because the quantity of organisms harvested in the prepara-
tion of the first inoculum was insufficient to inoculate all of the
mice, this inoculum was used to inoculate the mice of the
groups listed in Table 1 and a second inoculum was prepared
and used to inoculate the mice of the two groups shown in
Table 2, along with a small number of additional untreated
control mice. M. leprae from the inoculated mice were har-
vested and enumerated by Shepard’s method (16, 20) (Tables
1 and 2). Between 120 and 143 days after inoculation, the mice
of all of the groups were sacrificed and individual harvests of
M. leprae were performed from the inoculated footpads by
Shepard’s method (16, 20) (Tables 1 and 2). The purpose of
the statistical analysis applied to the resulting data was to
measure the likelihood that the groups of results being com-
pared were actually derived from a single population of results.
A nonparametric technique, the Mann-Whitney U test (24),
which is a technique for comparing two independent samples,
was employed, because parametric techniques such as Stu-
dent’s t test require the assumption that the results are nor-
mally distributed, an assumption that is not justified in this
case. On the other hand, the power of this technique is ap-
proximately equal to that of Student’s t test.
The results demonstrate that the cell wall skeleton, whether
suspended in PBS or emulsified in FIA, was not protective. On
the other hand, both the cytosol and membrane fractions as
well as the smaller dose of HKML conferred protection, de-
fined as a significantly smaller number of M. leprae per footpad,
whether the materials had been suspended in PBS or emulsi-
fied in FIA. The comparison of the two doses of HKML is
particularly interesting. Although different inocula were em-
ployed, making a direct comparison impossible, it is clear that
the dose of 2 109 HKML completely inhibited multiplication
of M. leprae. By way of explanation, if a harvest yields 0.089 
105 acid-fast bacilli (AFB) per footpad, only one organism has
been observed in 40 microscope fields (employing 12.5 ocu-
lars and a 100 oil-immersion objective); similarly, if only 2
AFB are observed in 40 microscope fields, the harvest has
yielded 0.18  105 AFB per footpad. These small yields do not
differ significantly from that of the inoculum of 5,000 M. leprae
per footpad and are occasionally encountered if mice are in-
oculated with 5  103 HKML. On the other hand, the dose of
2  107 HKML was not shown to be any more effective than
any of the effective fractions employed.
A number of workers have studied the protective properties
of various organisms and their components upon M. leprae
infection of immunocompetent mice. Most often employed in
these studies have been BCG and M. leprae itself. In early
publications (18, 21–23) Shepard reported that 5,000 viable
BCG administered either subcutaneously or intracutaneously
into the flank or into the left hind footpad conferred protection
against challenge with M. leprae in the right hind footpad 1 or
2 months later, as did much larger numbers of heat-killed
organisms. Protection was enhanced by emulsifying the organ-
isms in FIA and by repeated vaccination (17, 19). Vaccination
with viable BCG also conferred protection if the vaccine was
administered intracutaneously in the flank within the first 3
months after M. leprae challenge (21–23, 27–29). Although
Shepard was at first unable to demonstrate protection against
M. leprae challenge in the left hind footpad after initial infec-
tion with M. leprae in the right hind footpad, several workers
subsequently reported the presence of homologous immunity
in such animals, provided the second challenge was carried out
after a sufficiently long interval (11, 12). Subsequent studies
with cell wall preparations of BCG or M. leprae were contra-
dictory (7, 8), probably because methods of preparation had
not been standardized and because the degree of contamina-
tion of cell wall proper with soluble protective antigens varied
among preparations. Nowadays, with a more detailed under-
standing of the chemistry of the mycobacterial cell wall (2),
subcellular fractions of M. leprae are prepared in concordance
with this knowledge (13). For instance, cell walls are prepared
TABLE 1. Results of harvests of M. leprae from mice inoculated with the first inoculum
Materiala
No. of AFB per footpad (105)
Pb
Individual harvests Median
Control 33.6, 20.2, 18.9, 15.1, 11.5, 8.70, 6.39, 6.04, 5.06, 4.70, 4.62, 3.90, 3.37, 3.36, 1.69 6.04
FIA 8.17, 6.12, 3.55, 3.28, 2.31, 2.22, 1.60, 1.07, 0.89, 0.44, 0.18, 0.089, 0.089 1.60
CW skeleton 73.3, 13.5, 9.14, 8.61, 7.72, 7.46, 5.24, 1.51, 1.42 (2)c 7.59 0.782
CW skeleton in FIA 2.13, 2.04, 0.98, 0.80, 0.53 (2), 0.44, 0.27, 0.18, 0.089 (2), 0.089 0.48 0.0602
ML cytosol/MLSA 3.37, 2.75, 2.13, 1.78, 1.60, 1.24 (2), 1.15, 0.62, 0.44, 0.27, 0.18 1.24 0.00004
ML cytosol/MLSA in FIA 0.53, 0.36 (2), 0.27, 0.18 (3), 0.089 (2), 0.089 0.18 0.0107
ML membrane 4.44, 3.46, 2.84, 2.66, 2.04, 1.69, 1.33, 1.15, 0.98, 0.80 2.04 0.00034
ML membrane in FIA 0.44 (2), 0.27 (2), 0.18 (3), 0.089 (3) 0.18 0.0073
HKML (2  107) 1.60, 0.89, 0.80, 0.44, 0.36, 0.27, 0.18, 0.089 (2), 0.089 0.32 0.00003
HKML (2  107) in FIA 0.89, 0.62, 0.36 (2), 0.27, 0.18, 0.089, 0.089 (3) 0.22 0.00003
a CW, cell wall; ML, M. leprae.
b P, the probability that these results were drawn from the same population as those of the corresponding control, determined by means of the Mann-Whitney U
test.
c Number of footpads with indicated result; in all other cases, only a single footpad yielded the indicated result.
TABLE 2. Results of harvests of M. leprae from mice inoculated
with the second inoculum
Material
No. of AFB per footpad (105)
Pa
Individual harvests Median
Control 9.50, 3.91, 3.82, 2.31, 1.78 3.82
HKML (2  109) 0.089, 0.089 (9)b 0.089 0.00055
HKML (2  109) in FIA 0.18, 0.089 (11) 0.089 0.00022
a See footnote b to Table 1.
b See footnote c to Table 1.
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by centrifugation of disrupted bacilli at 27,000  g followed by
sucrose density gradient centrifugation (13), yielding a consis-
tent profile of cell wall-associated proteins. Cell walls (known
as MLCwA) prepared in this way have consistently been shown
to be protective (7, 8, 14). In this present work, we removed the
cell wall-associated proteins by extraction with sodium dodecyl
sulfate and have now shown that the residual cell wall skeleton
or core, a covalent complex composed of peptidoglycan, my-
colic acids, and arabinogalactan (2), is ineffective. In light of
the known role of mycobacterial lipids and carbohydrates to
evoke a T-cell response through the CD-1-restricted pathway
(1, 25) and other means (26), it is important to be able to state
that the dominant lipoglycoconjugate, the mycolyl-arabinoga-
lactan-peptidoglycan complex, is not protective in the leprosy
mouse model. Presumably, the presence of weakly T-cell-re-
active mycolic acids and arabinogalactan cannot compensate
for the virtual absence of highly immunogenic proteins.
The results clearly indicate that the variable protection as-
sociated with cell walls in the past had resulted from the asso-
ciated soluble proteins. Indeed, in the present work, the cyto-
solic and membrane proteins were again shown to be
protective. Like the cell wall skeleton, these were prepared in
a consistent, reproducible manner by centrifugation of the
initial 27,000  g supernatant at 100,000  g to obtain soluble
cytosol and insoluble, translucent membranes, respectively
(13). Thus, maximal protection against M. leprae challenge of
the mouse is conferred by a wide spectrum of cell proteins,
such as cytosolic, membranous, and cell wall-associated pro-
teins, and not by the core framework of the mycobacterial cell,
the mycolyl-arabinogalactan-peptidoglycan complex. In ex-
tending these studies to recombinant products, fused recom-
binant proteins, successful in conferring protection against tu-
berculosis (3, 4), are more promising than individual
recombinant proteins, which have consistently failed to confer
protection in this model.
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